Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

MedImmune To Continue FluMist Development; Wyeth Remains Undecided

  • News

Executive Summary

MedImmune is confident it can successfully develop FluMist on its own should Wyeth decide to back out of the companies' partnership for the intranasal flu vaccine

You may also be interested in...



MedImmune Gets Back FluMist: Physicians Will Be Focus Post-Wyeth

MedImmune is getting "back to basics" on FluMist promotional efforts with a focus on physician education now that the company has regained sole rights to the intranasal flu vaccine from Wyeth

MedImmune Gets Back FluMist: Physicians Will Be Focus Post-Wyeth

MedImmune is getting "back to basics" on FluMist promotional efforts with a focus on physician education now that the company has regained sole rights to the intranasal flu vaccine from Wyeth

FluMist Price Likely To Be Cut To $20-$25 Per Dose, MedImmune Says

MedImmune is considering reducing the price for the intranasal flu vaccine FluMist to $20-$25 per dose for the 2004-2005 season, CEO David Mott indicated during a first quarter conference call April 21

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Global Pharma Guidance Tracker – March 2024

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

See All
UsernamePublicRestriction

Register

PS043499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By